Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Merck
US Department of Justice
Medtronic
Harvard Business School
Boehringer Ingelheim
Daiichi Sankyo
Cerilliant

Generated: May 26, 2018

DrugPatentWatch Database Preview

BRIDION Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Bridion, and when can generic versions of Bridion launch?

Bridion is a drug marketed by Organon Sub Merck and is included in one NDA. There are three patents protecting this drug.

This drug has fifty-four patent family members in twenty-nine countries.

The generic ingredient in BRIDION is sugammadex sodium. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the sugammadex sodium profile page.
Summary for BRIDION
International Patents:54
US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 2
Clinical Trials: 37
Patent Applications: 1
DailyMed Link:BRIDION at DailyMed
Drug patent expirations by year for BRIDION
Pharmacology for BRIDION
Ingredient-typegamma-Cyclodextrins
Synonyms for BRIDION
343306-71-8
361LPM2T56
CHEBI:90953
DB06206
Org 25969
ORG-25969
SCHEMBL13917069
Sugammadex
Sugammadex [USAN:INN:BAN]
UNII-361LPM2T56

US Patents and Regulatory Information for BRIDION

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-002 Dec 15, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Organon Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-001 Dec 15, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Organon Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-002 Dec 15, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Organon Sub Merck BRIDION sugammadex sodium SOLUTION;INTRAVENOUS 022225-001 Dec 15, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Non-Orange Book US Patents for BRIDION

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,670,340 6-Mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Supplementary Protection Certificates for BRIDION

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C031/2008 Ireland ➤ Sign Up SPC031/2008: 20090428, EXPIRES: 20230724
2008000068 Germany ➤ Sign Up PRODUCT NAME: SUGAMMADEX ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
C0052 France ➤ Sign Up PRODUCT NAME: SUGAMMADEX SODIUM; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
47/2008 Austria ➤ Sign Up PRODUCT NAME: SUGAMMADEX; 6-PER-DEOXY-6-PER-(2-CARBOXYETHYL) THIO-Y-CYCLODEXTRIN UND PHARMAZEUTISCH VERTR√ĄGLICHES SALZ HIERVON
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Teva
Baxter
US Department of Justice
Chinese Patent Office
McKesson
Argus Health
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.